Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349, SHA:688505) agreed to subscribe for 200 million yuan of a structured deposit product from Ping An Bank, a Wednesday Hong Kong bourse filing said.
The move aims to allow the Chinese pharmaceutical company put its idle funds to better use.
The product has an expected annualized return rate of 0.65%-2.4% and will fall due in 89 days.